Form 4: Maze Therapeutics SVP Sells Shares Post-Option Exercise

Amy Bachrodt, SVP of Finance at Maze Therapeutics, executed a pre-planned sale of 5,000 common shares after exercising stock options on January 22, 2026.

Summary

• Amy Bachrodt, SVP of Finance at Maze Therapeutics, Inc. (MAZE), reported changes in her beneficial ownership of company securities.
• On January 22, 2026, Ms. Bachrodt acquired a total of 5,000 shares of common stock through the exercise of two stock options.
• The first option exercise involved 2,497 shares at an exercise price of $10.42 per share.
• The second option exercise involved 2,503 shares at an exercise price of $10.42 per share.
• Immediately following the option exercises on January 22, 2026, Ms. Bachrodt sold 5,000 shares of common stock.
• The shares were sold at a weighted average price of $45.5224 per share, with individual transaction prices ranging from $45.00 to $45.93.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Ms. Bachrodt on September 29, 2025.
• Following these transactions, Ms. Bachrodt beneficially owns 12,965 shares of common stock directly and 8,355 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sold shares, it was a pre-planned transaction under a Rule 10b5-1 plan, indicating a structured approach to managing equity compensation rather than a sudden loss of confidence. The executive realized a substantial profit from the option exercise and sale.

Positives

• The SVP of Finance realized a significant profit by exercising stock options at $10.42 per share and selling the resulting common stock at a weighted average price of $45.5224 per share.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a structured approach to managing equity compensation rather than an opportunistic sale.

Negatives

• The sale of 5,000 shares by a senior executive, even if pre-planned, represents a reduction in direct insider ownership, which can sometimes be perceived neutrally to slightly negatively by the market.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details an individual executive's equity compensation management and does not provide broader industry context or trends.

Related Party Transactions

• The reported transactions involve the SVP of Finance, Amy Bachrodt, exercising stock options and selling common stock of Maze Therapeutics, Inc., which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The sale of shares by a senior executive, even if pre-planned, slightly increases the public float and can be a data point for investors assessing insider sentiment, though the impact is likely minimal given the transaction size and pre-planned nature.
• Employees: The transaction reflects the realization of value from equity compensation, which is a common component of executive pay packages.

Key Dates

Keywords

Maze Therapeutics, MAZE, Insider Trading, Form 4, Stock Options, Share Sale, Rule 10b5-1 Plan, Executive Compensation